Compare SOPH & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | PACB |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 419.8M |
| IPO Year | 2021 | 2010 |
| Metric | SOPH | PACB |
|---|---|---|
| Price | $5.30 | $1.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.50 | $1.67 |
| AVG Volume (30 Days) | 86.1K | ★ 6.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $23.09 | $11.32 |
| Revenue Next Year | $19.57 | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $2.59 | $0.85 |
| 52 Week High | $5.70 | $2.73 |
| Indicator | SOPH | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 53.04 |
| Support Level | $4.55 | $1.52 |
| Resistance Level | $5.30 | $1.79 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 64.85 | 54.26 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.